NOT KNOWN DETAILS ABOUT HEMGENIX

Quantity of qualified clients: CDEC discussed the uncertainty in the amount of sufferers with moderately extreme to intense hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific specialists consulted by CADTH indicated that some patients who are classified as obtaining gentle or average condition may have a intense bleeding phen